Fcγ Receptors: Old Friends and New Family Members  by Nimmerjahn, Falk & Ravetch, Jeffrey V.
Immunity 24, 19–28, January 2006 ª2006 Elsevier Inc. DOI 10.1016/j.immuni.2005.11.010ReviewFcg Receptors: Old Friends
and New Family MembersFalk Nimmerjahn1 and Jeffrey V. Ravetch1,*
1Laboratory of Molecular Genetics and Immunology
The Rockefeller University
New York, New York 10021
Although cellular receptors for immunoglobulins were
first identified nearly 40 years ago, their central role in
the immune response was discovered only in the last
decade. They are key players in both the afferent and
efferent phase of an immune response, setting thresh-
olds for B cell activation, regulating the maturation of
dendritic cells, and coupling the exquisite specificity
of the antibody response to innate effector pathways,
such as phagocytosis, antibody-dependent cellular
cytotoxicity, and the recruitment and activation of in-
flammatory cells. Moreover, because of their general
presenceas receptor pairs consistingof activatingand
inhibitory molecules on the same cell, they have be-
come a paradigm for studying the balance of positive
and negative signals that ultimately determine the out-
come of an immune response. This reviewwill summa-
rize recent results in Fc-receptor biology with an em-
phasis on data obtained in in vivo model systems.
The mammalian immune system has evolved to defend
the organism against pathogenic microbes, layering the
specificity of adaptive responses on the ancestral path-
ways of innate immunity. This complexity exists to pro-
vide discrimination between self and nonself and to in-
sure that immune responses are tightly regulated, thus
avoiding autotoxicity and uncontrolled inflammation.
Multiple checkpoints have been identified that func-
tion to insure an orderly progression through an im-
mune response and thereby prevent the generation of
self-destructive processes. A common theme that has
emerged from the study of these checkpoints is the re-
quirement for the establishment of discrete thresholds
that define narrow windows of response. One mecha-
nism to achieve these thresholds is for the coexpression
of receptors with common ligand binding properties but
divergent signaling capacities, coupling activating re-
ceptors with an inhibitory counterpart, thereby setting
thresholds for immune cell activation (Ravetch, 2003).
Immune complexes (IC) consisting of IgG antibodies
have long been recognized to have potent immunoregu-
latory functions ranging from a strong enhancement to
complete suppression of antibody responses (Heyman,
2000), in addition to their more overt roles as effector
molecules for the elimination of foreign antigens. These
divergentactivitiesof IgGscannowbeexplained through
the selective engagement of specific FcgRs on discrete
cell types, which result in either arrest or progression of
an immune response, determined by the specific check-
point and threshold achieved. This review will focus on
our current understanding of the diversity of these recep-
*Correspondence: ravetch@rockefeller.edutors and their in vivo biological function in both tolerance
and immunity.
In all mammalian species studied to date, four differ-
ent classes of Fc receptors have been defined: FcgRI
(CD64), FcgRII (CD32), FcgRIII (CD16), and FcgRIV.
Whereas FcgRI displays high affinity for the antibody-
constant region and restricted isotype specificity, FcgRII
and FcgRIII have low affinity for the Fc region of IgG but
a broader isotype binding pattern (Ravetch and Kinet,
1991; Hulett and Hogarth, 1994), and FcgRIV is a recently
identified receptor, conserved in all mammalian species
(Figure 1) with intermediate affinity and restricted sub-
class specificity (Mechetina et al., 2002; Davis et al.,
2002; Nimmerjahn et al., 2005). The low-affinity Fc-
receptor genes are clustered in close proximity to each
other in syntenic regions on chromosome 1 in humans,
chimpanzees, and mice, on chromosome 13 in rats, and
on chromosome 38 in dogs (Figure 1). Whereas only sin-
gle copies of the low-affinity Fc-receptor genes are pre-
sent in most species, duplications and diversification
processes have led to the presence of multiple genes
in the human genome (Qiu et al., 1990). Unfortunately,
most likely due to their highly homologous sequences,
many genome databases do not list these as separate
genes but incorrectly as allelic versions of one gene.
Functionally, there are two different classes of Fc re-
ceptors: the activation and the inhibitory receptors,
which transmit their signals via immunoreceptor tyro-
sine-based activation (ITAM) or inhibitory motifs (ITIM),
respectively (Ravetch and Lanier, 2000). The paired ex-
pression of activating and inhibitory molecules on the
same cell is the key for the generation of a balanced im-
mune response. Additionally, it has only recently been
appreciated that the IgG Fc receptors show significant
differences in their affinity for individual antibody iso-
types, rendering certain isotypes more strictly regulated
than others (Nimmerjahn et al., 2005). This represents
a second layer of complexity and is of major importance
for understanding Fc-receptor-dependent antibody-
mediated effector functions in vivo and for the design of
antibody-based therapies. We will focus on recent key
findings that define the specificity of IgG Fc receptors
and their role in tolerance and immunity. We will only
briefly mention developments in the rapidly evolving field
of Fc-receptor homolog proteins; we direct the reader to
several excellent recent reviews covering that topic in
greater detail (Davis et al., 2002, 2005).
The Inhibitory Fcg Receptor IIB
Fcg receptor IIB (FcgRIIB) together with other receptors
such as PIR-B, KIRs, CTLA-4, PD-1, CD5, and CD22, be-
long to the family of immune inhibitory receptors. These
proteins can be found on a wide variety of immune effec-
tor cells, share similar properties, and are important reg-
ulators of their activating counterparts (Ravetch and
Lanier, 2000). The loss of these negative regulators leads
to imbalanced immune responses resulting in auto-
immunity and overt autoimmune disease (Tivol et al.,
1995; Penninger et al., 1995; Takai et al., 1996; O’Keefe
et al., 1999; Nishimura et al., 1999; Bolland and Ravetch,
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20Figure 1. Genomic Organization of the Low-Affinity Fc-Receptor Genes
(A) The genomic organization of the Fc-receptor locus in mouse, rat, dog, chimpanzee, and humans is shown according to the ensembl database
(http://www.ensembl.org). Colors indicate genes that were predicted to be orthologs. Based on these homologies, we are suggesting the indi-
cated nomenclature. Arrows indicate the orientation of the gene. Cen indicates the localization of the centromer. Brackets indicate that the pres-
ence of the gene is assumed.
(B) Cladogram showing the alignment of selective Fcg receptors of humans (h), macaques (mac), mice (m), and rats.
(C) Alignment of the FcgRIV-related proteins in humans, macaques, and rats. Colors indicate sequence homologies and the type of amino acids
(red, basic; blue, small and hydrophobic; magenta, acidic; green, hydroxyl, amine, and weakly basic). 1, mouse FcgRIV (accession number,
Q8R2R4); 2, rat FcgRIV (accession number, Q6XPU4); 3, human FcgRIIIA (accession number, P08637); 4, macaque FcgRIV (accession number,
Q8SPW2). Abbreviations: EC1, EC2: extracellular domains 1 or 2 of FcgRIV.
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212000). FcgRIIB is a single-chain receptor that carries an
ITIM motif in its cytoplasmic domain, a hallmark of this
inhibitory protein family. It functions through the recruit-
ment of the inositol phosphatase SHIP through binding
to an SH2 site generated on the FcgRIIB ITIM as a conse-
quence of the transphosphorylation that is initiated upon
its coligation to an ITAM-bearing receptor. With the ex-
ception of T cells and NK cells, FcgRIIB is expressed
on all cells of the immune system, and it is the only clas-
sical Fc receptor on B cells where it regulates activating
signals delivered by immune complexes retained on the
FDC to the B cell receptor (BCR). Furthermore, several
Fc-receptor-related molecules, e.g., FcRX and FcRH1-5,
are expressed on human and mouse B cells. Despite sig-
nificant sequence homology to classical Fc receptors,
attempts to demonstrate antibody binding activity for
these molecules have been unsuccessful, rendering
FcgRIIB the only antibody binding Fc receptor on B cells.
Nevertheless, these Fc-receptor-related molecules show
a restricted expression pattern during different stages of
B cell development and might become important new
markers for defining B cell developmental stages or B
cell malignancies (Davis et al., 2005).
FcgRIIB as a Regulator of B Cell Activation
As a consequence of its role in regulating BCR signals,
which ultimately will decide whether a B cell proliferates,
class switches, and matures into an antibody-secreting
plasma cell, FcgRIIB has been suggested to play an im-
portant role in maintaining peripheral tolerance (Bolland
and Ravetch, 1999; Ravetch and Lanier, 2000). When
coligated with the BCR, it triggers two ITIM-dependent
signaling pathways that inhibit cell activation and prolif-
eration. While regulation of cell activation is dependent
on the recruitment of SHIP to the ITIM motif, which ulti-
mately leads to the inhibition of calcium-dependent sig-
naling pathways, control of proliferation, however, seems
to involve SHIP-independent signaling pathways, in-
cluding the adaptor molecule Dok and MAP kinases (Bol-
land and Ravetch, 1999). Besides these ITIM-dependent
signaling events, the isolated crosslinking of FcgRIIB
on B cells leads to B cell apoptosis via ITIM- and SHIP-
independent and c-Abl-family kinase-dependent path-
ways (Pearse et al., 1999; Tzeng et al., 2005). The ca-
pacity of FcgRIIB to trigger B cell apoptosis has been
proposed to be another mechanism for controlling B cell
responses and maintaining self tolerance by deletion of
low-affinity or self-reactive B cells. This hypothesis was
supported by the generation of FcgRIIB-deficient mice
that spontaneously develop a lupus-like disease charac-
terized by the production of autoantibodies and prema-
ture death due to severe glomerulonephritis (Takai
et al., 1996; Bolland and Ravetch, 2000). It should be
noted, however, that this autoimmune phenotype is
strain dependent, indicating that other epistatic modi-
fiers are involved in disease susceptibility and severity
(Nguyen et al., 2002; Bolland et al., 2002). In line with this
role of FcgRIIB in maintaining tolerance, autoimmune-
prone mouse strains such as NZB, NOD, BXSB, and
MRL express reduced levels of this receptor on activated
and germinal-center B cells, which has been attributed to
a polymorphism in the promoter of this gene (Jiang et al.,
1999, 2000; Pritchard et al., 2000; Xiu et al., 2002). More
recently, a similar polymorphism in the human FcgRIIBpromoter that is linked to lupus has been identified. This
polymorphism leads to decreased transcription and sur-
face expression of FcgRIIB on activated B cells of human
lupus patients (Blank et al., 2005). Additionally, a poly-
morphism in the transmembrane domain of FcgRIIB is
linked to human lupus in several racial groups (Kyogoku
et al., 2004; Siriboonrit et al., 2003; Chu et al., 2004). It has
been suggested that this allelic variant of the inhibitory
receptor loses its function due to the inability to associ-
ate with lipid rafts (Floto et al., 2005; Kono et al., 2005).
Although FcgRIIB is also expressed on other inflam-
matory immune effector cells such as neutrophils,
monocytes, and macrophages, the fact that the auto-
immunity observed in FcgRIIB-deficient animals is a B
cell-autonomous phenotype is supported by several
independent lines of evidence. First, transfer of FcgRIIB-
deficient bone marrow into irradiated RAG or IgH knock-
out recipients leads to the development of autoimmu-
nity. In these animals, the monocytic compartment still
expressed FcgRIIB while it was absent from peripheral
B cells (Bolland and Ravetch, 2000). Second, by increas-
ing FcgRIIB expression on B cells to wild-type levels
by retroviral transduction of bone marrow derived from
the autoimmune-prone mouse strains NZM, BXSB, and
FcgRIIB knockout mice, it was possible to restore toler-
ance and thus prevent the development of fatal auto-
immune disease (McGaha et al., 2005). Interestingly,
restoration of FcgRIIB expression to wild-type levels on
approximately 40% of peripheral B cells was sufficient
to prevent the development of autoantibodies and auto-
immune glomerulonephritis, a result confirmed by the
generation of mixed bone marrow chimeras (McGaha
et al., 2005). The fact that it was not necessary to restore
FcgRIIB function on all B cells highlights the threshold
nature of autoimmunity. This finding has important im-
plications for the design of therapeutic approaches, as
it suggests that despite the complex nature of autoim-
mune diseases, therapeutic effects are achievable by
targeting specific cell populations.
The B cell stage(s) at which FcgRIIB exerts its function
as a gatekeeper of self tolerance has recently been de-
fined. Autoreactive B cells can be generated at several
stages during B cell development (Figure 2). There is ac-
cumulating evidence that FcgRIIB mediates its function
during late stages of B cell maturation, thus represent-
ing a distal checkpoint. Through the analysis of an anti-
DNA knockin model, it was established that the absence
of FcgRIIB resulted in the expansion of IgG-positive
plasma cells secreting autoreactive antibodies (Fu-
kuyama et al., 2005). FcgRIIB deficiency did not impact
on early events in the bone marrow like receptor editing,
nor did it prevent the development of IgM-positive au-
toreactive B cells. After class switching to IgG, however,
FcgRIIB was essential to prevent the expansion of au-
toreactive B cells and their maturation into plasma cells.
Taking the considerably higher pathogenic potential of
IgG compared to IgM antibody isotypes into account,
this relatively late stage of FcgRIIB-mediated negative
regulation might be sufficient to prevent the initiation
of severe autoreactive processes.
These results suggest a model in which several cen-
tral and peripheral checkpoints prevent the emergence
of autoreactive B cells and their maturation into plasma
cells that could secrete pathogenic antibodies (Figure 2).
Immunity
22Figure 2. Checkpoints Regulating Self-Reac-
tive B Cells during Development
During early B cell development, central
checkpoints delete B cells with an autoreac-
tive B cell receptor (shown in red) in the bone
marrow. Some of these autoreactive B cells
can be rescued by ongoing BCR rearrange-
ments (receptor editing). Autoreactive B cells
that escape into the periphery or are gener-
ated de novo during the germinal center reac-
tion are controlled by peripheral checkpoints
such as deletion or rendering harmful cells
anergic. FcgRIIB represents a late checkpoint
that controls the expansion of IgG- positive
autoreactive cells and their differentiation into
plasma cells.Central checkpoints including receptor editing, deletion,
and anergy of self-reactive BCR species insure that the
majority of B cells with an autoreactive BCR are deleted
in the bone marrow (Meffre et al., 2000; Goodnow et al.,
2005; Grimaldi et al., 2005); this occurs independently of
FcgRIIB. It is widely accepted, however, that this pro-
cess is incomplete and self-reactive cells can escape
into the periphery, in a background-dependent manner.
Thus, Balb/c mice are more efficient in editing than
C57Bl/6 mice, making the later a more permissive strain
for the development of autoimmunity. Consistent with
this observation, FcgRIIB-deficient mice on the Balb/c
background did not develop spontaneous autoimmu-
nity; in contrast, this deficiency of an inhibitory receptor
on the C57Bl/6 background resulted in the emergence of
a highly penetrant, fatal lupus-like disease. Moreover,
autoreactive B cells can be generated de novo in the pe-
riphery during the germinal center reaction (Ray et al.,
1996; Bona and Stevenson, 2004). Therefore, additional
checkpoints are of major importance to prevent the ac-
cumulation of autoreactive cells in the periphery. Fur-
thermore, the expansion of class-switched self-reactive
antibodies that can trigger a wide variety of inflamma-
tory effector functions needs to be tightly regulated (Dij-
stelbloem et al., 2001; Ravetch and Bolland, 2001). Here,
FcgRIIB might serve as the final barrier to prevent these
B cells with potentially harmful BCR specificities from
maturing into plasma cells that would otherwise induce
tissue pathology by secretion of large amounts of self-
reactive antibodies.
FcgRIIB on Dendritic Cells
While FcgRIIB appears to function in a B cell-autono-
mous manner to regulate autoreactive cells in the pe-
riphery, another cell type where FcgRIIB may play an im-
portant role in regulating immunity and tolerance are the
dendritic cells (DC). Depending on their maturation state,
DCs can either tolerize or activate naive T cells (Steinman
et al., 2003). Several groups have shown that immune
complexes can function as potent mediators of DC mat-
uration and can enhance efficient antigen presentation
of endocytosed antigen (Regnault et al., 1999; Dhodap-
kar et al., 2002; Rafiq et al., 2002; Groh et al., 2005).
FcgRIIB expression on DCs controls immune complex-
mediated DC maturation, as DCs derived from FcgRIIB-
deficient mice showed an enhanced potential to gener-
ate antigen-specific T cell responses in vitro and in vivo
(Kalergis and Ravetch, 2002). Those studies suggestedthat in the steady state, FcgRIIB could function to pre-
vent spontaneous maturation of DCs and that manipula-
tion of this pathway could result in optimized immuno-
therapeutic and vaccination strategies by overcoming
this negative regulatory effect of FcgRIIB on DCs.
With the recent generation of monoclonal antibodies
that specifically block immune complex binding to hu-
man FcgRIIB, it has become possible to test this hypoth-
esis. Incubation of human dendritic cells with an FcgRIIB
blocking antibody was sufficient to induce DC matura-
tion by immune complexes normally present in plasma,
as suggested by the upregulation of costimulatory mol-
ecules and the enhanced generation and activation of
tumor-specific T cells (Dhodapkar et al., 2005; Boruchov
et al., 2005). This indicates that blocking the inhibitory
Fc receptor on DCs might indeed be a strategy for gen-
erating stronger and probably longer lasting immune re-
sponses. It should be noted, however, that immature
DCs are continuously tolerizing self-reactive T cells that
escape negative selection in the thymus. Systemic ad-
ministration of an FcgRIIB blocking antibody might per-
turb this pathway and lead to expansion of autoreactive
cells. To test this hypothesis, the development of novel
animal models with targeted deletion of Fc receptors
in dendritic cells or other selective cell populations will
be essential. Additionally, mice and man differ in the
specific FcRs they express on DCs. Animals carrying
the human Fc receptors in place of their mouse counter-
parts will be important preclinical tools for assessing
the in vivo activity of blocking antibodies for human
Fc receptors. In summary, these studies suggest that
FcgRIIB may function as an important regulator of DC
activation by setting thresholds that prevent the spon-
taneous maturation of dendritic cells (Figure 3) and
thereby promote steady-state tolerance. This activity,
on one hand, prevents the activation and expansion of
self-reactive T and B cells but on the other may limit the
generation of strong antitumor or pathogen-specific
immune responses. Manipulation of this pathway thus
offers an approach to enhanced vaccines and immuno-
therapeutics.
FcgRIIB Controls Innate Immune Effector
Cell Activation
In addition to its autoregulatory role in the afferent re-
sponse, FcgRIIB is an important modulator of inflamma-
tory effector cells such as mast cells, neutrophils, and
macrophages during the efferent phase of an immune
Review
23Figure 3. Factors that Influence Fc-Receptor-Dependent Activities of Antibody Isotypes
(A) Individual antibody isotypes have different affinities for activating and inhibitory Fc receptors (see text). Red arrows indicate preferential in-
teractions of the indicated antibody isotypes with cellular Fc receptors; black arrows indicate lower affinity interactions. In the case of IgG2a, the
broken red arrow indicates that the interaction might be blocked as FcgRI is continuously occupied with monomeric IgG2a. The table summa-
rizes the actual A/I ratios based on the affinities of the individual Fc receptors for the respective antibody isotypes.
(B) The ratio of activating to inhibitory Fc receptors on immune cells such as DCs, macrophages, and neutrophils is regulated by exogenous
factors. Cytokines like IL-4, IL-10, or TGF-b upregulate FcgRIIB, thereby setting high thresholds for cell activation, whereas inflammatory medi-
ators downregulate the inhibitory (shown in red) and upregulate the activating (shown in green) Fc receptors. For therapeutic approaches,
FcgRIIB-mediated inhibition might be circumvented by using FcgRIIB-blocking antibodies.response (Ravetch and Bolland, 2001; Dijstelbloem et al.,
2001). On these cell types, FcgRIIB is coexpressed with
activating Fc receptors of varying affinities and isotype
specificities and negatively regulates activating signals
delivered by these receptors. This role of FcgRIIB is
apparent in animals deficient in this receptor. Lack of
FcgRIIB leads to enhanced immune complex-mediated
inflammation and phagocytosis as demonstrated by
an enhanced Arthus reaction, systemic IgG- and IgE-
induced anaphylaxis, anti-GBM glomerulonephritis,immunothrombocytopenia (ITP), hemolytic anemia,
collagen-induced arthritis, and IgG-mediated clearance
of pathogens and tumor cells. In some of these models,
both increased autoantibody production due to FcgRIIB
deficiency on B cells and heightened effector cell re-
sponses are likely to contribute to the observed pheno-
type. As will be discussed below, the magnitude of
FcgRIIB modulation is strictly isotype dependent and
predictable based on the relative affinities of IgG sub-
types for activating and inhibitory receptors.
Immunity
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In contrast to the single-chain inhibitory Fc receptor, ac-
tivating FcgRs (with the exception of human FcgRIIA)
cannot transmit activating signals in the absence of an
accessory chain, the common g chain (g chain), that car-
ries an ITAM motif required for triggering cell activation.
Aggregation of activating receptors by immune com-
plexes leads to tyrosine phosphorylation of the ITAM
motif by members of the Src-kinase family and sub-
sequent recruitment of SH2-containing kinases such
as members of the Syk-kinase family. These early events
ultimately lead to the recruitment of phosphatidylinositol
3-kinase (PI3-K) and phospholipase-Cg (PLCg), which
trigger protein kinase C (PKC) activation and sustained
calcium elevation (Ravetch, 2003). Moreover, the g chain
plays a major role in the assembly of activating FcRs,
mediating cell-surface expression of activating Fc recep-
tors. FcgRI, FcgRIII, and FcgRIV are dependent on g
chain expression; thus, deletion of this receptor sub-
unit leads to the functional loss of all activating Fc recep-
tors and several other non-FcR-related proteins such as
PIR-A and NK cell cytotoxicity receptors (Moretta et al.,
2001; Ravetch, 2003). Expectedly, g chain knockout
animals were demonstrated to have significant defects
in antibody-dependent effector cell responses such as
phagocytosis of ICs, ADCC, and inflammatory responses
(Takai et al., 1994; Sylvestre and Ravetch, 1994; Clynes
and Ravetch, 1995; Park et al., 1998; Zhang et al., 2004).
In contrast to these dramatic effects in g chain knockout
mice, deletion of the individual activating Fcg receptors I
or III resulted in less pronounced phenotypes, especially
for effector responses involving the IgG2a and IgG2b
antibody isotypes.
The only IgG isotype that could consistently be as-
signed to an individual activating Fc receptor in vivo was
IgG1. Here the deletion of the low-affinity receptor
FcgRIII abrogated IgG1-mediated effector functions in
various models like arthritis, glomerulonephritis, IgG-
dependent anaphylaxis, IgG-mediated hemolytic ane-
mia, and immunothrombocytopenia (Hazenbos et al.,
1996; Meyer et al., 1998; Fossati-Jimack et al., 2000; Ji
et al., 2002; Bruhns et al., 2003; Fujii et al., 2003; Nimmer-
jahn et al., 2005). Importantly, however, under many cir-
cumstances, such as host response to viral or bacterial
infections (Coutelier et al., 1987; Schlageter and Kozel,
1990; Markine-Goriaynoff and Coutelier, 2002; Taborda
et al., 2003), antibody-mediated cytotoxicity, or anti-
body-based therapy (Kipps et al., 1985; Fossati-Jimack
et al., 2000; Uchida et al., 2004; Nimmerjahn et al., 2005;
Nimmerjahn and Ravetch, 2005), the most potent anti-
body isotypes were of the IgG2a and IgG2b isotype.
Therefore, a thorough understanding of how these iso-
types exert their function was essential.
Considering the isotype specificities of the high-affin-
ity FcgRI (binding exclusively IgG2a) and the low-affinity
FcgRIII (binding IgG1, IgG2a, and IgG2b) (Ravetch and
Kinet, 1991; Hulett and Hogarth, 1994), these two recep-
tors seemed to be the obvious candidates responsible
for IgG2a and IgG2b effector functions. Although there
was some suggestion that FcgRI and III might partici-
pate in a limited fashion in IgG2a-mediated effector re-
sponses (Ioan-Facsinay et al., 2002; Barnes et al., 2002),
the majority of studies concluded that IgG2a- and
IgG2b-triggered effects occur independently of thesetwo receptors, but in a g chain-dependent manner
(Hazenbos et al., 1996; Meyer et al., 1998; Fossati-
Jimack et al., 2000; Uchida et al., 2004; Nimmerjahn
et al., 2005). Especially in the case of IgG2a, these results
seemed to be surprising, as FcgRI shows a high affinity
for this isotype (KA: 10
8–109 M21). However, the in-
creased affinity allowed this receptor to bind monomeric
IgG2a as efficiently as immune complexes (ICs), indicat-
ing that newly generated ICs would be expected to have
only limited access to FcgRI (Figure 3A).
The dominant view, therefore, suggested that other
effector mechanisms such as activation of the comple-
ment cascade might mediate the in vivo effects of these
isotypes. Indeed, IgG2a and IgG2b can efficiently acti-
vate the complement cascade in vitro (Duncan and Win-
ter, 1988). However, several studies with mice deficient
in a variety of complement proteins such as C2, C3,
or C4 failed to demonstrate a major involvement of
the complement cascade (Ravetch and Clynes, 1998;
Uchida et al., 2004; Nimmerjahn and Ravetch, 2005).
On the other hand, deletion of the g chain abrogated
IgG2a and IgG2b effector functions in a variety of pas-
sive models of cytotoxicity, strongly arguing for the ex-
istence of other g-chain-dependent Fc receptors. Geno-
mic analysis of the recently assembled mouse database
identified one gene that showed 63% overall amino acid
identity to human FcgRIIIA and an even greater identity
in the antibody binding extracelluar domain and was
called Fc-receptor-like 3 (Fcrl3), CD16-2, or FcgRIV
(Mechetina et al., 2002; Davis et al., 2002; Nimmerjahn
et al., 2005). This gene has now been shown to be
a bona fide IgG Fc receptor and is called FcgRIV to des-
ignate that fact.
FcgRIV: A Family Member with Distinct Activity
The FcgRIV gene is located on mouse chromosome 1
tightly linked to FcgRIIB and FcgRIII (Figure 1). A predic-
tion of ortholog proteins in other species shows that
there are related proteins in humans (FcgRIIIA), chim-
panzees, macaques, rats, dogs, cats, pigs, and cows
(Figure 1 and not shown), with the highest level of simi-
larity to the rat (80%) and the human ortholog. It requires
g chain for its surface expression and, as has been
described for other g-chain-dependent Fc receptors,
crosslinking of FcgRIV by immune complexes induces
activating signaling pathways leading to sustained cal-
cium flux (Ravetch and Bolland, 2001; Nimmerjahn
et al., 2005).
FcgRIV is highly expressed on neutrophils, mono-
cytes, macrophages, and dendritic cells and is unde-
tectable on mast cells, NK cells, and T and B cells. Sim-
ilar to other activating Fc receptors, inflammatory stimuli
(LPS) and TH-1 cytokines (IFN-g) can upregulate FcgRIV;
in contrast, TH-2 cytokines IL-4, IL-10, or TGF-b downre-
gulate FcgRIV cell-surface expression. After induction of
DC maturation, FcgRIV, together with other activating
Fc receptors, is downregulated. An important difference
between mouse FcgRIV and the human FcgRIIIA is that
FcgRIV is not expressed on NK cells. Human neutrophils
do not express FcgRIIIA but rather FcgRIIA as their
dominant activating FcgR.
The ligand specificity for FcgRIV revealed that it
bound IgG2a and IgG2b with intermediate affinity (KA:
2–33 107 M21), but not IgG1 or IgG3 antibody isotypes.
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able stable binding to monomeric IgG, leaving it acces-
sible for immune complex binding. Comparison of the
affinity of IgG2a and 2b for FcgRIV and FcgRIIB revealed
a 1–2 order of magnitude higher affinity for the activation
receptor as compared to its inhibitory counterpart, thus
predicting that these subclasses would be significantly
less sensitive to FcgRIIB-mediated negative regulation
(Figure 3A). Moreover, even if coexpressed with FcgRIII,
IgG2a and IgG2b ICs would preferentially engage
FcgRIV due to its 20–40 times higher affinity and due
to the strong FcgRIIB-imposed negative regulation of
FcgRIII. Consistent with this notion, blocking FcgRIV
function in vivo greatly impaired the pathogenic effects
of IgG2a and IgG2b antibodies in passive models of
antibody-mediated platelet depletion or tumor cell de-
struction (Nimmerjahn et al., 2005; Nimmerjahn and
Ravetch, 2005). It will be important to determine the
role of FcgRIV in other passive and active models of
antibody-mediatedcytotoxicityand inflammation,where
FcgRI- and FcgRIII-independent effects have been ob-
served, such as anti-CD20 antibody-mediated B cell de-
pletion, hemolytic anemia, or certain models of glomeru-
lonephritis and arthritis.
These studies suggest that even if several activating
Fc receptors with the same isotype specificity are pres-
ent on the same cell, only those Fc receptors will be en-
gaged that show the optimal affinity for the respective
isotype (Figure 3A). Therefore, IgG1 immune complexes
will trigger only FcgRIII, as it is the only activating Fc re-
ceptor that can bind IgG1; IgG2a and IgG2b, despite
their ability to bind FcgRI (in the case of IgG2a) or FcgRIII
(in the case of IgG2a and 2b), will functionally be depen-
dent on FcgRIV as FcgRI will be occupied by monomeric
IgG2a and the low affinity of FcgRIII will not result in pro-
ductive engagement at normal serum concentration of
these isotypes. These same principles also apply for
the human system, where it has been shown that human
FcgRIIIA has a higher affinity for IgG1 as compared to
human FcgRIIA. In addition, the presence of allelic var-
iants that show differential affinities for the specific anti-
body isotypes further supports this concept (Dijstel-
bloem et al., 2001).
Another Layer of Complexity: Isotype-Specific
Negative Regulation by FcgRIIB and the
Influence of Cytokines
Based on the recognition of FcgRIV as a highly con-
served member of the IgG FcR family, the affinity of the
individual Fc receptors for the respective antibody iso-
types has been readdressed (Nimmerjahn et al., 2005).
These studies predict that, depending on the antibody
isotype, individual activating Fc receptors will be differ-
entially regulated by the low-affinity inhibitory Fc recep-
tor IIB (Figure 3A). Based on these affinities, IgG1 would
be expected to be the most strictly regulated IgG isotype
with a ratio of FcgRIII to FcgRIIB (A/I-ratio) affinity of 0.1
(Figure 3A). In contrast, due to the higher affinity of
FcgRIV, these ratios are 70 or 7 for IgG2a and IgG2b,
suggesting that these isotypes should be more potent
in vivo. Consistent with this hypothesis, it has been ob-
served that in many model systems where isotype
switch variants were used, the IgG2a and IgG2b variants
were more potent than IgG1or IgG3 (Kipps et al., 1985;Fossati-Jimack et al., 2000; Nimmerjahn and Ravetch,
2005). Moreover, deletion of the inhibitory Fcg receptor
impacted most strongly on antibodies of the IgG1 iso-
type (Clynes et al., 2000; Nimmerjahn and Ravetch,
2005). The in vivo activity of an IgG antibody, therefore,
can be predicted based on its A/I ratio. While there are
several factors that can influence these basic A/I ratios,
such as basal expression levels of activating versus in-
hibitory receptors and the modulation of these ratios
by cytokines, the magnitude of those components are
of secondary significance when compared to the contri-
bution of affinity. Thus, IgG2a antibodies are relatively in-
sensitive to these effects, while IgG1 is quite sensitive to
modest changes in A/I ratios. For example, in active
models of antibody-mediated inflammation, the steady-
state ratios will be changed in favor of the activating Fc
receptors (Figure 3B). Inflammatory mediators, such as
IFN-g and C5a, can upregulate activating Fc receptors
and at the same time reduce FcgRIIB expression levels
(Guyre et al., 1983; Shushakova et al., 2002). Under these
circumstances, autoreactive IgG1 antibodies are capa-
ble of causing severe damage. In contrast, TH-2 cyto-
kines like IL-4, IL-10, or TGF-b upregulate the inhibitory
Fc receptor and decrease expression of the activating
Fc receptors on innate immune effector cells (Okayama
et al., 2000; Pricop et al., 2001; Radeke et al., 2002; Tri-
dandapani et al., 2003; Nimmerjahn et al., 2005). Under
these conditions, isotypes that have a low or moderate
A/I ratio (IgG1 and IgG2b) would be expected to lose
more activity than those with a high ratio, such as IgG2a.
High-dose intravenous g globulin (IVIG) provides a com-
pelling example of the generality of this concept. The
antiinflammatory activity of this preparation has recently
been shown to be linked to its ability to upregulate
FcgRIIB expression on effector macrophages in models
of ITP and rheumatoid arthritis (RA). For IgG1, this mod-
ulation alone is sufficient to convert a pathogenic anti-
body to a nonpathogenic isotype, consistent with the
low A/I ratio for this subclass in which modest changes
in FcgRIIB expression will raise the threshold required
for effective IgG1 crosslinking of FcgRIII. It should be
noted, however, that cytokine-mediated regulation of
FcR expression is cell type-specific. IL-4, for example,
while upregulating FcgRIIB expression on myeloid cells,
downregulates FcgRIIB expression on activated B cells
(Rudge et al., 2002).
Recent data suggest that this paradigm holds true
for human IgG antibodies as well. Human clinical trials
with antibodies directed against tumor cell-surface pro-
teins, such as CD20, revealed that patients with the high-
affinity FcgRIIIA or FcgRIIA alleles, resulting in a higher
A/I ratios, responded significantly better to antibody
therapy with increased survival and time to relapse (Car-
tron et al., 2002; Weng and Levy, 2003; Weng et al., 2004).
The challenge for future antibody-based immunothera-
peutic approaches will be to select or, preferably, design
antibody isotypes thatcan triggereffector functionssuch
as ADCC reactions even under nonfavorable A/I ratios.
A critical factor in such Fc engineering is knowledge of
the FcR-expression profile of the relevant effector cells
mediating the biologically relevant response and the im-
pact of both disease and therapy on the modulation of
these receptors. Moreover, knowledge of the dominant
antibody isotypes involved in an autoimmune disease
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tivating Fc receptor, thereby allowing the identification of
therapeutic targets. Thus, since murine lupus models
display a dominance of IgG2a and IgG2b subclasses, it
is tempting to speculate that FcgRIV is the responsible
activating Fc receptor in these disease models, as well.
It seems likely that in human lupus, where IgG1 and IgG3
isotypes dominate the anti-DNA response, and IgG2
and IgG3 are the major isotypes in kidney immune
complex deposits, multiple activating Fc receptors are
responsible for antibody-mediated inflammation (Mad-
dison, 1999; Tsao, 2003). Indeed, allelic variants of human
FcgRIIA and IIIA that change the affinity of these recep-
tors for IgG isotypes have been suggested to be risk
factors for developing lupus in certain populations
(Tsao, 2003).
The regulation of FcR expression by cytokines is cou-
pled to the regulation of isotypes by these same cyto-
kines. Thus, TH1 cytokines such as IFN-g induce class
switching to IgG2a, whereas TH2-type cytokines (IL-4)
induce class switching to IgG1 (Coffman et al., 1989; Fin-
kelman et al., 1990). As these cytokines also influence
Fc receptor expression, the pathogenicity of an auto-
immune response will be determined by both cytokine-
mediated regulation of class switching and the changes
of expression levels of the responsible activating versus
inhibitory Fc receptors.
Conclusions
Research in the field of Fc-receptor biology over the last
decade has established the in vivo role of these recep-
tors during various phases of an immune response.
With the identification of mouse FcgRIV, a more com-
plete and consistent picture of Fc-receptor biology in the
mammalian system emerges and previously conflicting
results can now be explained. It has become clear that
the efficiency of therapeutic as well as the pathogenicity
of autoimmune antibodies will be determined by the
strength of the interaction with cellular Fc receptors.
Factors that influence this interaction are the actual af-
finity of antibody isotypes for Fc receptors and the ex-
pression level of the activating/inhibitory receptor pairs.
Analysis of murine model systems has established that
despite the complex nature of these interactions, it is
clearly possible to manipulate their outcome. The chal-
lenge for the future will be to translate this knowledge
into optimized therapeutic approaches. In the case of
the inhibitory Fc receptor, these therapeutic scenarios
might include enhancing inhibitory Fc-receptor expres-
sion on B cells to suppress the generation of auto-
reactive plasma cells or blocking FcgRIIB activity on
dendritic cells to generate stronger antitumor or anti-
pathogen immune responses. Activating Fc receptors
can be similarly manipulated such that blocking their ac-
tivity in the case of destructive autoimmune processes
would be desirable or enhancing antibody binding to
these receptors to obtain stronger antibody-dependent
cellular cytotoxicity reactions for the elimination of in-
fected or malignant cells.
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